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Abstract
Background: HIV status disclosure is a difficult emotional task for HIV-infected persons and may create the
opportunity for both social support and rejection. In this study, we evaluated the proportions, patterns, barriers and
outcomes of HIV- 1 status disclosure among a group of women in Uganda.
Methods: An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a
study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in “The Nevirapine
Repeat Pregnancy (NVP-RP) Study” at the Makerere University-Johns Hopkins University Research Collaboration,
Kampala-Uganda, between June 2004 and June 2006.
Results: Of the 85 women interviewed, 99 % had disclosed their HIV status to at least one other person. Disclosure
proportions ranged between 1 % to employer(s) and 69 % to a relative other than a parent. Only 38 % of the
women had disclosed to their sex partners. Women with an HIV-infected baby were more likely than those with an
uninfected baby to disclose to their sex partner, OR 4.9 (95 % CI, 2.0 –11.2), and women were less likely to disclose
to a partner if they had previously disclosed to another relative than if they had not, OR 0.19 (95 % CI, 0.14–0.52).
The most common reasons for non-disclosure included fear of separation from the partner and subsequent loss of
financial support 34 %, and not living with the partner (not having opportunities to disclose) 26 %. While most
women (67 %) reported getting social support following disclosure, 22 % reported negative outcomes (neglect,
separation from their partners, and loss of financial support). Following disclosure of HIV status, 9 % of women
reported that their partner (s) decided to have an HIV test.
Conclusion: Results from this study show high overall HIV disclosure proportions and how this disclosure of HIV
status can foster social support. However, proportions of disclosure specifically to male sex partners were low,
which suggests the need for interventions aimed at increasing male involvement in perinatal care, along with
supportive counseling.
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Background
With the introduction of antiretroviral drugs, significant
successes have been achieved in the reduction of the risk
of HIV transmission from mother to child during preg-
nancy, delivery and breast feeding in resource-limited
settings [1–10]. Despite these successes, significant prob-
lems remain that may impact the implementation of
HIV mother-to-child transmission (MTCT) interven-
tions in developing countries.
In sub-Saharan Africa, reported proportions of women
who disclose their HIV status to sex partners vary
widely. Previous studies have found that between 17 %
and 86 % of HIV-infected individuals share HIV test re-
sults (HIV status) with their sex partners [11–16] with
women tested in the context of their antenatal care
being less likely to disclose their HIV status to their sex
partners than non-pregnant women (16.7 % versus
32 %). In a prevention of mother-to-child transmission
(PMTCT) of HIV trial conducted in Tanzania, Kilewo et
al. found that only 17 % of the women shared their HIV
status with their partner [17]. Such low proportions of
disclosure have implications for PMTCT programs as
the optimal uptake and adherence to such programs are
difficult for such women whose partners are either
unaware of or do not understand the benefits of partici-
pation in PMTCT programs [18–21].
Research conducted in a variety of settings has shown
that there are a number of barriers that HIV-infected
individuals face in sharing their HIV test results with
friends, family, and, most importantly, sex partners. These
barriers include fears of abandonment and loss of
economic support, discrimination, accusations of infi-
delity, violence, upsetting family members, and blame
[12, 14, 22, 23]. Despite these fears, disclosure of HIV
status to sex partners remains an important public health
goal as emphasized by the World Health Organization
[24] and the Centers for Disease Control and Prevention
[25] in their HIV testing and counseling protocols. In
general HIV disclosure is an essential aspect in the
prevention, care, treatment and support for HIV-infected
persons [26]. In the context of PMTCT, disclosure to male
partners has been associated with improved adherence to
PMTCT regimens [27], better infant feeding practices
[28], safer sex practices, and increased male partner
testing [29]. Conversely, HIV-infected women who have
not disclosed their HIV-1 status to their partner are more
likely than other HIV-infected women to have suboptimal
adherence to PMTCT regimens [26, 30, 31], higher drop-
out rates from PMTCT programs [32], and fewer infants
tested for HIV-1[9]. Given the pivotal role of disclosure in
PMTCT, understanding the problems faced by HIV in-
fected women concerning HIV status disclosure is critical
in informing future MTCT intervention program activities
in resource limited settings.
The aim of this study was to describe the proportions,
patterns, barriers and outcomes of HIV status disclosure
among HIV-infected women participating in a study of
mother-to-child HIV-1 transmission rates among NVP-
experienced compared to NVP-naïve women, “The Nevi-
rapine Repeat Pregnancy (NVP-RP) Study”.
Methods
The Nevirapine Repeat Pregnancy (NVP-RP) study
The NVP-RP study was an observational study of
mother-to-child HIV-1 transmission conducted at
Makerere University-Johns Hopkins University (MU-
JHU) Research Collaboration, Kampala – Uganda be-
tween June 2004 and June 2006, the details of which
have been previously published [33]. Briefly, the main
objectives of the NVP-RP study were to determine HIV
transmission rates in infants born to HIV-infected
women who received single dose NVP in a previous
pregnancy as well as in the repeat pregnancy (NVP-ex-
perienced) and to compare these transmission rates in
infants born to HIV-infected women who had not re-
ceived prior single dose NVP (NVP-naïve). Two groups
of HIV-positive women, previously pregnant while in the
HIV Network for Prevention (HIVNET) 012 trial[2] or
PMTCT Program (retrospective group) or currently preg-
nant (prospective group), were enrolled in this study. The
prospective mother and infant group included women
who were pregnant at the time of study enrollment and
were either NVP-experienced or NVP-naïve.
Women were recruited between 28 and 40 weeks of
gestation from the antenatal clinics of Mulago Na-
tional Referral Hospital in Kampala and followed for
one year. As part of the study, women received coun-
seling and support for HIV status disclosure during
the one year follow-up period.
Procedures
An exit interview was conducted among 85 HIV-1
infected mothers at their 12 month (final) visit in the
prospective arm of the NVP-RP study at MU-JHU
Research Clinic after obtaining separate informed
consent. Data were collected between November 2005
and June 2006. Disclosure was defined as the individual
revealing her HIV status to her primary sex partner,
parent, sibling, other relatives, employer, or friends, at
any time since diagnosis. Proportions of women who
had disclosed to a significant other (including a primary
sex partner), as well as predictors and outcomes of
disclosure were determined.
Measurements
Data was collected using a pre-tested standardized ques-
tionnaire. The primary outcome variable for this study
was self-reported HIV status disclosure recorded as
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‘yes’or ‘no’. Other outcome variables included disclosure
outcomes for example receipt of social support, partner
deciding to test, neglect and separation, etc. Explanatory
variables included socio-demographic characteristics (age,
income, education level, religion, marital status, and
occupation), relationship factors (reaction from signifi-
cant other[s], partner’s HIV status (as reported by the
participant), disclosure barriers, and psychosocial fac-
tors (stigma, and social support).
Single response multiple choice questions were asked
to determine disclosure patterns: ‘Have you ever told
any of the following people about your HIV status?’
The outcome of disclosure to the primary sex partner
or significant other was then assessed. Data were col-
lected on disclosure outcomes based on responses to
the following question: ‘What happened when you
disclosed your HIV status?’ For participants who had
not disclosed to their sex partner the reasons for non-
disclosure were probed. Participants who knew whether
their partners had ever tested for HIV were asked
whether their partners had tested HIV positive as well
‘Has your partner ever been tested for HIV? If yes, did
your partner test positive?’
Statistical methods
STATA version 13.0 was used for data analyses. All
variables were checked for missing data and inconsisten-
cies. Distribution of the data using summary measures
and graphical displays were examined to identify outliers
and verified against source documentation. Participants
were compared for baseline characteristics, disclosure
proportions, barriers and outcomes of disclosure using
descriptive statistics.
To determine predictors of disclosure a logistic regres-
sion model was run with disclosure as the outcome vari-
able. Bivariate analyses were used to determine the
presence of statistically significant associations between
explanatory variables and the outcome variable. To iden-
tify independently associated factors, multiple logistic
regression was employed. Factors associated with dis-
closure at a p value of less than 0.1 in the bivariable ana-
lysis were subsequently entered into backward stepwise
logistic regression models to determine which factors
were independently associated with disclosure. A p-value
of ≤ 0.05 was considered statistically significant in the
final model.
Ethical considerations
The study was approved by institutional review boards
at the Uganda Virus Research Institute, Uganda National
Council of Science and Technology in Uganda and the
Centers for Disease Control and Prevention in Atlanta,
Georgia. Written informed consent for study participa-
tion was obtained from all participants.
Results
Table 1 presents the demographic characteristics of
the 85 women who participated in this study. There
were no missing data or outliers. Women who partici-
pated had a mean age of 28.7 years and 50 % had com-
pleted primary school. The majority (60 %) were living
with their partner in a consensual relationship, and a
lower proportion was married (13 %), single (13 %) or
had divorced or separated from their spouses at the
time of the interview (14 %). Among 66 women who
were married or were living in consensual relation-
ships, 50 % were housewives or homemakers, who did
not work outside the home. Only 39 % of the 85
women were aware of their spouses or partners ever
Table 1 Demographics of participants in the Nevirapine Repeat
Pregnancy sub-study on HIV status disclosure, Uganda, 2004–2006
Characteristic Mean or proportion (n [%]), N = 85










Primary school completed 43 (50)
Secondary school completed 31 (37)
Tertiary school completed 6 (7)
Occupation





Other (waitress, housemaid) 15 (18)
Partner ever tested for HIV
Yes 33 (39)
No 23 (27)
Do not know 29 (34)
HIV status of partner
Partner positive 26 (31)
Partner negative 7 (8)
Unknown (partner not known
to have tested)
52 (61)
HIV status of the study child
HIV infected 15 (18)
Not HIV infected 70 (82)
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testing for HIV, and 31 % reported having known HIV
positive partners.
Disclosure proportions
Of the 85 women interviewed, 99 % had disclosed
their HIV status to at least one other person, and
only one woman had never told anyone that she was
HIV infected. Of the 84 women who had disclosed
their HIV status, 38 % had disclosed to their sex part-
ners, 66 % to their parents, 69 % to other relatives,
and 30 % to friends. Only 1 % had disclosed to her
employer (Fig. 1).
Barriers to partner disclosure
Among the 53 women who had not yet disclosed their
HIV status to their partners reported barriers to disclos-
ure included fear of separation and subsequent loss of
financial support (34 %), separated from or not living
with partner (not having opportunities to disclose)
(26 %), and stigmatization (2 %). Other reasons, included
fear of causing worry to the partner or fear of a harmful
reaction from the partner (e.g., partner causing self-
harm or becoming abusive) and not yet being ready to
disclose (38%) (data not shown).
Outcomes of disclosure
Outcomes of disclosure included receipt of social
support (67%) neglect/separation from partner (8 %),
negative reactions (violence, stigmatization, confidants
telling others) (9 %), loss of monetary support (5 %),
and other reactions, including indifference (especially
from partners), partner not believing the woman and
friends motivated to go for HIV testing (13 %)
(Table 2). Among the 32 women who disclosed their
HIV status to their partner, only 25 % reported that
their partner subsequently underwent HIV testing as a
result of the disclosure the remaining 75 % women
reported that their partners had already had an HIV
test before the disclosure.
All women who had disclosed to their partners knew
the partner’s HIV status. One woman in a sero-discordant
relationship knew her partner’s HIV status but had not
disclosed her own status to him.
Predictors of disclosure to partner
Figure 2 shows proportions of HIV status disclosure
by selected characteristics. In bivariate analyses HIV
status disclosure to the sex partner was positively as-
sociated with having an HIV-infected study baby, OR
6.7 (95 % CI, 1.4 – 14.2), not having disclosed to a
relative (other than a parent), OR 6.1 (95 % CI, 1.7 –
9.2) and being a housewife or homemaker, OR 4.1
(95 % CI, 1.3 – 13.2). After adjusting for age, educa-
tion level, and marital status, the association
remained significant with having an HIV-infected
baby (adjusted OR 4.9 [95 % CI, 2.0 – 11.2]) and not
having previously disclosed to a relative other than a
parent (adjusted OR 0.19 [95 % CI, 0.14 – 0.52]), but
not with being a housewife or homemaker.
Fig. 1 HIV status disclosure among women in the Nevirapine Repeat Pregnancy sub-study Uganda, 2004–2006
Table 2 Outcome of disclosure of participants in the Nevirapine
Repeat Pregnancy sub-study, Uganda, 2004-2006
Outcomea n (%) N = 85
Received social support 57 (67 %)
Partner decided to test 8 (9 %)
Neglect/separated from partner 7 (8 %)
Loss of monetary support from partner 4 (5 %)
Other negative reactions (violence,
stigmatization, confidants telling others)
8 (9 %)
Other outcomesb 11 (13 %)
aOne or more outcomes may be indicated by each participant
b“Other” includes; partner indifferent, partner did not believe her, friends did
not believe her, sibling advised her not to tell partner, initially separated bed
rooms with partner, friends were encouraged to go for HIV testing as well
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Discussion
The general level of disclosure in this study was very
high, with 99 % of the women reporting having disclosed
to at least one other person. As would be expected, the
women disclosed selectively, with the majority disclosing
to only one person, most often to a parent (67 %) or a
relative other than a parent (69 %).
These findings are comparable to other studies in
Africa, with disclosure proportions of greater than 90 %
to at least one other person [12, 34–36]. In a study
conducted in Uganda, Nakayiwa et al. found that 97 %
of HIV infected patients in an HIV care program had
ever disclosed their HIV status to at least one other
person [34]. Similarly, two other studies in South Africa
found that more than 90 % of HIV infected study par-
ticipants had disclosed their HIV status to one or more
person [12, 35].
Despite the high levels of disclosure, in general, the
proportion of women disclosing to a sex partner was
relatively low in this study, with only 38 % of all women
having disclosed to their partners. In addition, most
women did not know their partner’s HIVstatus, which is
similar to findings from previous studies [15, 37]. The
reasons given for non-disclosure to the partner included
not being ready to disclose, not having sufficient time or
opportunities to disclose (e.g., separation from partner,
not having enough time with partner), and fear of nega-
tive consequences from the disclosure (e.g., fear of being
stigmatized, partner causing self-harm, partner becom-
ing abusive). However, the majority of the women who
had disclosed reported getting social support, and some
reported that their partners decided to test for HIV
following disclosure. Negative outcomes were less com-
mon but not rare, and included neglect and/or separ-
ation from partner, violence from partner, stigmatization
by relatives, confidants disclosing to others, and indiffer-
ence – especially from partners.
The relatively low proportion of women who disclosed
to their sex partner in our study suggests considerable
complexities around issues of partner disclosure. Partner
factors and relationship dynamics remained the key to
understanding why women do or do not disclose their
HIV status. Notably, women with an HIV–infected study
baby, or who had not previously disclosed to a relative
were more likely than other women to disclose to their
partners. Women who disclosed to a relative could have
been less likely to subsequently disclose to their partners
due to the fact that they received the support they felt
they needed. Another explanation may be that women
who wanted to disclose but were reluctant to tell their
partner may have felt that their only alternative was to
disclose to a relative. In the same way, in order to get
the support needed in the care for an HIV infected child,
women with an HIV infected study baby may have found
it necessary to disclose to their partners. The relatively
low prevalence of disclosure to sex partners observed in
this study suggests a potential risk for transmission in
cases where the male partner is uninfected or of un-
known status. This is particularly so if non-disclosure
leads to not using condoms during sex and perhaps
placing the partner at risk of HIV infection [38]. These
gaps in disclosure to sex partners highlight the need for
guidance regarding counseling women on disclosing
their HIV status, including for cases in which the woman
Fig. 2 Proportion of women disclosing HIV serostatus to sex partners, by selected characteristic, Nevirapine Repeat Pregnancy sub-study,
Uganda, 2004–2006
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might be at risk for negative consequences such as
violence and loss of housing or of financial support.
Our study had some limitations. First, the parent study
was not designed to assess disclosure as a primary out-
come; information from women participating in a peri-
natal research study may have limited generalizability.
Participants had been diagnosed over a year before the
exit interview and had undergone several counseling
sessions as part of the primary study protocol, which
encouraged them to disclose to a sex partner or other
close friend or relative. This counseling may explain the
high proportions of disclosure reported in this study.
This finding is consistent with results from a study by
Mansergh et al., who found that the length of time since
diagnosis was positively correlated with disclosure [39].
Additionally, our study relied on self-report, which made
the information subject to social desirability reporting
bias. To minimize social desirability bias, women were
counseled by trained counselors in a supportive and
non-judgmental way.
Conclusion
Results from this study show high general HIV
disclosure proportions and how this disclosure of HIV
status can foster social support. The study findings may
also suggest areas for further intervention research. Spe-
cifically, intervention models aimed at increasing male
involvement in perinatal care, along with providing sup-
portive counseling may be feasible approaches to in-
creasing the proportion of women disclosing their HIV
status to their male partners.
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